The TAS120-101 trial (FOENIX-CCA2)

This international Phase I/II trial is for those patients who have FGF/FGFR gene abnormalities in their tumour, and for whom there are no other available therapies. The trial is currently open and recruiting at four UK sites, with further sites planned to open during 2019:

Sarah Cannon Research Institute
London W1G 6AD

Contact: Professor Tobias Arkenau
Tel: 0203 219 5200
Email: Tobias.Arkenau@HCAHealthcare.co.uk

To see information on the Sarah Cannon Research Institute, go to:
http://sarahcannonresearch.co.uk/

University College London Hospital
London W1T 7HA

Contact Professor John Bridgewater
Tel: 020 3447 9093
Fax: 020 3447 9055
Email: j.bridgewater@ucl.ac.uk

Guy’s and St Thomas’ NHS Foundation Trust
London SE1 9RT

Contact: Professor Debashis Sarker
Tel: 020 7188 8103
Email: earlyphaseresearchteam@gstt.nhs.uk

University Hospital Bristol NHS Foundation Trust
Bristol, BS1 3NU

Contact:  Dr. Helen Winter
Email: Helen.Winter@UHBristol.nhs.uk

For further details on the TAS120-101 (FOENIX-CCA2) trial, go to:
https://clinicaltrials.gov/show/NCT02052778
and
https://www.ukctg.nihr.ac.uk and search for trial number: NCT02052778

Back to previous page